# VLA1601 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vla1601

> VLA1601, sponsored by Valneva SE (VALN): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | VLA1601 |
| Codes | VLA1601 |
| Sponsor | Valneva SE (VALN) https://sec-api.dev/companies/valn/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Mar 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-03-24, last confirmed 2025-03-24.
- SEC Form 10-K (accession 0001628280-25-014522): "In March 2024, we initiated a Phase 1 clinical trial to investigate the safety and immunogenicity of our optimized vaccine candidate." https://www.sec.gov/Archives/edgar/data/1836564/000162828025014522/valn-20241231.htm

### 1H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-03-20, last confirmed 2025-03-20.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-013977): "In addition to the CHIM study, LimmaTech is planning to initiate a Phase 2 pediatric study in LMICs in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1836564/000162828025013977/valnevapr3-20x2025.htm

### late 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-03-20, last confirmed 2025-03-20.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-013977): "•First data readout for Lyme disease Phase 3 VALOR study expected at the end of 2025" https://www.sec.gov/Archives/edgar/data/1836564/000162828025013977/valnevapr3-20x2025.htm

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-02-19, last confirmed 2026-03-18.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-019159): "•First Phase 3 data readout for Lyme disease vaccine candidate (VLA15) anticipated in the first half of 2026, with regulatory submissions expected to follow as planned by Pfizer, subject to positive results oIf approved, VLA15 will be the fourth vaccine successfully developed by Valneva and subsequent commercialization by Pfizer would enable Valneva to further expand and accelerate its pipeline of innovative vaccines in line with the Company's strategic vision" https://www.sec.gov/Archives/edgar/data/1836564/000162828026019159/a2026_03x18xfyx2025xresult.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009463): "•First Phase 3 data readout for Lyme disease vaccine candidate anticipated in the first half of 2026, with regulatory submissions expected to follow as planned by Pfizer, subject to positive results oIf successful, VLA15 will be the fourth vaccine developed by Valneva and its successful commercialization by Pfizer would enable Valneva to further expand and accelerate a pipeline of innovative vaccines in line with its strategic vision" https://www.sec.gov/Archives/edgar/data/1836564/000162828026009463/a2026_02x19xfy2025xrevcash.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vla1601.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VLA1601 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vla1601

```bibtex
@misc{secapidev_pdufa_vla1601_20261116,
  title        = {VLA1601 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vla1601}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vla1601_20261116","title":"VLA1601 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vla1601","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
